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The concept of susceptibility genes common to different autoimmune diseases is now ﬁrmly established with
previous studies demonstrating overlap of loci conferring susceptibility to type 1 diabetes (T1D) with both
Coeliac disease and multiple sclerosis. Rheumatoid arthritis (RA) is an archetypal autoimmune disease
and we, therefore, targeted putative T1D susceptibility loci for genotyping in UK RA cases and unrelated con-
trols. A novel RA susceptibility locus at AFF3 was identiﬁed with convincing evidence for association in a
combined sample cohort of 6819 RA cases and 12 650 controls [OR 1.12 95% conﬁdence intervals (CI)
1.07–1.17, P 5 2.8 3 10
27]. Association of two previously described loci (CTLA-4 and 4q27) with RA was
also replicated (OR 0.87, 95% CI 0.82–0.94, P 5 1.1 3 10
24 and OR 0.86, 95% CI 0.79–0.94, P 5 5.4 3 10
24,
respectively). These ﬁndings take the number of established RA susceptibility loci to 13, only one of
which has not been associated with other autoimmune diseases.
INTRODUCTION
Rheumatoid arthritis (RA) is a disease in which uncontrolled
inﬂammation of synovial joints may cause progressive joint
damage and consequent long-term disability. It is a typical
autoimmune disease, being characterized by the elaboration
of auto-antibodies to immunoglobulins (rheumatoid factor)
and cyclic citrullinated peptides (anti-CCP antibodies) and
by genetic associations with the class II region of the major
histocompatibility complex. Genome wide association (GWA)
and subsequent validation studies have successfully identiﬁed
a number of novel RA susceptibility loci but it is already clear
that simply following up the top tiers of signiﬁcantly associ-
ated markers from such studies is unlikely to identify all the
relevant disease-associated loci (1–6). Clustering of auto-
immune diseases, including type 1 diabetes (T1D) and RA,
is apparent in families and it has already been established
that RA and T1D share common susceptibility loci (7). For
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(SNP) in the PTPN22 gene (PTPN22 R620W) has been
associated with susceptibility to both diseases as has poly-
morphism at the interleukin 2 receptor alpha (IL2RA) locus
(1,8). Given that T1D is an autoimmune disease for which a
large number of susceptibility variants have already been
identiﬁed, we sought to explore the hypothesis that putative
T1D susceptibility genes/loci are also associated with RA.
RESULTS
T1D putative genetic susceptibility loci were selected for
investigation from information available from a previous
study (8), excluding markers mapping to the INS (not a
strong candidate gene for RA), CLEC2D2 (associated by
multi-locus imputation analysis only) and PTPN22 (RA data
published previously) (2) genes (8,9). Eighteen single nucleo-
tide polymorphisms (SNPs) mapping to 14 distinct loci were
genotyped in 3962 UK RA cases and 3531 unrelated UK con-
trols. A Bonferroni correction of 14 was applied to correct for
the number of loci studied, resulting in a P-value threshold of
0.004 for claims of signiﬁcance. The sample size had .80%
power to identify association at this threshold assuming the
same effect sizes as reported previously for T1D for most of
the loci investigated (Supplementary Material, Table S1) (8,9).
Of the 18 SNPs tested, four variants mapping to three loci
(AFF3, CTLA4 and IL2/21) showed evidence for association
with RA (Table 1). These included two SNPs [rs10865035
OR 1.13 (1.06–1.21), P ¼ 4.0   10
24 and rs1160542 OR
1.12 (1.05–1.20), P ¼ 0.001] mapping to the AFF3 locus,
which are highly correlated (r
2 ¼ 0.97) with each other. Con-
ditional logistic regression analysis suggested that the primary
effect is from rs10865035. A perfect proxy for this variant was
genotyped as part of the Wellcome Trust Case Control
Consortium (WTCCC) study (rs9653442) and also showed
evidence for association in that cohort of 1860 RA cases
and 2920 controls (trend P ¼ 4.8   10
24) (1). For the
rs10865035 SNP, data was available from an additional
cohort of 997 RA cases, recruited as part of an inception
cohort study of RA outcome and 6199 controls with published
genotype frequencies available (8). In total, therefore, data
was available for 6819 RA cases and 12 650 controls. Allele
frequencies were similar across the three control cohorts
with no evidence of heterogeneity (P ¼ 0.39). Hence, a com-
bined analysis across all samples was undertaken and con-
ﬁrmed strong evidence for association of this locus with RA
susceptibility (OR 1.12 95% CI 1.07–1.17, P ¼ 2.8   10
27).
A variant mapping to the CTLA-4 gene showed the strongest
evidence for association with RA in the current cohort
(rs3087243 OR 0.87, 95% CI 0.82–0.94, P ¼ 1.1   10
24).
There have been previous reports of association of this
variant with RA but ﬁndings have been inconsistent, probably
reﬂecting the modest sample sizes used in many of the pre-
vious investigations (10,11). Combining the results from two
previous well-powered studies with the current data, the
SNP is conﬁrmed as being associated with RA susceptibility
[OR 0.88 (0.83–0.93), P ¼ 2.6   10
26] (Fig. 1) (11).
A SNP mapping within the IL2-IL21 locus on chromosome
4q27, previously reported to be associated with T1D, Coeliac
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Human Molecular Genetics, 2009, Vol. 18, No. 13 2519disease and RA, was also associated with RA susceptibility in
the current series (9). As reported previously, it was the
common allele that predisposed to disease [rs6822844 OR
0.86, (0.79–0.94), P ¼ 5.4   10
24].
The three loci show evidence for association with T1D and
RA and are strong candidates for pan-autoimmunity suscepti-
bility genes. If these loci predispose to autoimmunity in
general, it might be expected that associations would be stron-
ger in subsets of patients with auto-antibodies. However, fol-
lowing stratiﬁcation by presence of auto-antibodies, the
strength of associations was similar between auto-antibody
positive and negative individuals at all three SNPs indicated
by the overlapping conﬁdence intervals (Table 2).
Finally, although the common allele of a non-synonymous
SNP (rs6897932) mapping to the IL7R gene previously
associated with both T1D and multiple sclerosis was
somewhat over-represented in RA cases (OR 0.90, 95% CI
0.84–0.97; trend P ¼ 0.007), this did not achieve statistical
signiﬁcance at the corrected P-value threshold (8,12,13).
DISCUSSION
The concept of pan-autoimmunity susceptibility genes is now
ﬁrmly established with recent reports of overlap between T1D
and Coeliac disease as well as T1D and multiple sclerosis
(14,15). By targeting variants with suggestive evidence for
association with T1D, we have identiﬁed a novel association
of the AFF3 locus with RA susceptibility. In addition, associ-
ation of two other loci, the CTLA4 and IL2-IL21 regions, has
also been conﬁrmed.
The association of variants in the AFF3 locus with suscep-
tibility to RA has not previously been described. The variant
was selected for genotyping because there was suggestive evi-
dence for association with T1D in one large case–control
series (P ¼ 5.0  10
26), although this was not subsequently
replicated in a smaller family-based study (8). However, we
have found evidence for association of the variant in three
independent case–control series including UK patients with
RA and controls with combined analysis reaching a threshold
that some regard as achieving genome-wide signiﬁcance (P ,
5   10
27). The associated variants map to the 50 and promoter
region of the AFF3 gene, which is strongly conserved in
Figure 1. Meta-analysis of current data for the rs3087243 SNP in the CTLA-4
gene with data from a previous study in two well-powered cohorts of RA
patients and controls.
T
a
b
l
e
2
.
R
e
s
u
l
t
s
f
o
r
S
N
P
s
w
i
t
h
e
v
i
d
e
n
c
e
f
o
r
a
s
s
o
c
i
a
t
i
o
n
w
i
t
h
T
1
D
a
n
d
R
A
a
f
t
e
r
s
t
r
a
t
i
f
y
i
n
g
b
y
a
u
t
o
-
a
n
t
i
b
o
d
y
s
t
a
t
u
s
i
n
R
A
p
a
t
i
e
n
t
s
S
N
P
L
o
c
u
s
C
o
n
t
r
o
l
g
e
n
o
t
y
p
e
c
o
u
n
t
s
:
n
(
%
)
1
/
1
1
/
2
2
/
2
C
C
P
n
e
g
þ
R
F
n
e
g
g
e
n
o
t
y
p
e
c
o
u
n
t
s
:
n
(
%
)
1
/
1
1
/
2
2
/
2
O
R
(
9
5
%
C
I
)
a
C
C
P
p
o
s
þ
/
o
r
R
F
p
o
s
g
e
n
o
t
y
p
e
c
o
u
n
t
s
:
n
(
%
)
1
/
1
1
/
2
2
/
2
O
R
(
9
5
%
C
I
)
a
r
s
1
0
8
6
5
0
3
5
A
F
F
3
8
5
4
(
2
9
.
1
)
1
4
8
8
(
5
0
.
6
)
5
9
6
(
2
0
.
3
)
1
0
4
(
2
7
.
6
)
1
7
7
(
4
6
.
9
)
9
6
(
2
5
.
5
)
1
.
1
4
(
0
.
9
8
–
1
.
3
3
)
6
6
1
(
2
4
.
1
)
1
3
5
2
(
4
9
.
3
)
7
2
8
(
2
6
.
6
)
1
.
1
4
(
1
.
0
6
–
1
.
2
2
)
r
s
3
0
8
7
2
4
3
C
T
L
A
4
8
9
2
(
2
9
.
2
)
1
5
2
3
(
5
0
.
0
)
6
3
4
(
2
0
.
8
)
1
1
2
(
2
9
.
8
)
1
9
5
(
5
1
.
9
)
6
9
(
1
8
.
4
)
0
.
9
4
(
0
.
8
1
–
1
.
1
)
5
1
8
(
3
5
.
4
)
1
3
0
3
(
4
5
.
9
)
9
3
8
(
1
8
.
6
)
0
.
8
7
(
0
.
8
1
–
0
.
9
4
)
r
s
6
8
2
2
8
4
4
I
L
2
_
2
1
2
3
2
6
(
6
7
.
3
)
1
0
0
3
(
2
9
.
0
)
1
2
5
(
3
.
6
)
2
7
7
(
7
2
.
1
)
9
7
(
2
5
.
3
)
1
0
(
2
.
6
)
0
.
8
1
(
0
.
6
6
–
1
.
0
)
2
0
6
1
(
7
0
.
9
)
7
7
5
(
2
6
.
7
)
7
1
(
2
.
4
)
0
.
8
5
(
0
.
7
7
–
0
.
9
3
)
R
F
,
r
h
e
u
m
a
t
o
i
d
f
a
c
t
o
r
;
C
C
P
,
a
n
t
i
-
c
y
c
l
i
c
c
i
t
r
u
l
l
i
n
a
t
e
d
p
e
p
t
i
d
e
a
n
t
i
b
o
d
y
;
P
o
s
,
p
o
s
i
t
i
v
e
;
N
e
g
,
n
e
g
a
t
i
v
e
.
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
f
o
r
w
h
o
m
a
u
t
o
-
a
n
t
i
b
o
d
y
d
a
t
a
a
v
a
i
l
a
b
l
e
:
R
F
p
o
s
¼
2
4
7
0
;
R
F
n
e
g
¼
9
3
4
;
A
n
t
i
-
C
C
P
p
o
s
¼
1
4
4
6
;
A
n
t
i
-
C
C
P
n
e
g
¼
6
7
4
;
C
C
P
n
e
g
þ
R
F
n
e
g
(
a
u
t
o
-
a
n
t
i
b
o
d
y
n
e
g
a
t
i
v
e
)
¼
4
0
0
;
C
C
P
p
o
s
þ
/
o
r
R
F
p
o
s
(
a
u
t
o
-
a
n
t
i
b
o
d
y
p
o
s
i
t
i
v
e
)
¼
2
9
5
8
.
a
O
R
(
9
5
%
C
I
)
¼
o
d
d
s
r
a
t
i
o
a
n
d
9
5
%
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
s
.
2520 Human Molecular Genetics, 2009, Vol. 18, No. 13evolution and is preferentially expressed in lymphoid cells
(16). It encodes a nuclear factor that can interact with DNA
and contains transcriptional activation domains, making it a
strong candidate autoimmunity gene.
Our ﬁndings also support association of the CTLA4 gene
with RA susceptibility. CTLA4 is a co-stimulatory receptor
expressed on activated T cells which down-regulates the T
cell response. The rs3087243 SNP maps within the 30 region
of the CTLA-4 gene and previous functional studies have
identiﬁed a correlation between the ratio of soluble to full
length CTLA4 mRNA levels with genotype at this variant
(17). Interestingly, the fusion protein, Abatacept (Orencia), a
biologic drug with proven efﬁcacy in RA, is a CTLA-4 ana-
logue, highlighting the fact that relatively modest genetic
effects may identify targets for treatment which are highly
effective in large numbers of patients (18).
A region on chromosome 4q27 also showed evidence for
association with RA susceptibility in our UK series. The
region exhibits substantial linkage disequilibrium encompass-
ing both the IL2 and IL21 genes. Since both are good candi-
dates as autoimmunity susceptibility genes, identifying the
causal polymorphism to determine exactly how it predisposes
to autoimmune diseases will be challenging.
It is interesting to note that the IL7R gene showed a trend
towards association with RA. The rs6897932 SNP is located
in exon 6 and is associated with increased exon skipping
resulting in an alteration in the ratio of the membrane-bound
to soluble receptor. The IL7 pathway is important in T cell
growth and plays a role in regulating cytokine production
and, interestingly, expression of IL7R has been correlated
with disease activity in peripheral blood mononuclear cells
from patients with RA (19). However, association in other
RA data sets is required before this locus can be conﬁdently
conﬁrmed as an RA susceptibility gene.
In summary, by targeting loci with prior evidence for associ-
ation with T1D, we have identiﬁed a novel association of AFF3
with RA susceptibility. We have also conﬁrmed association of
RA with two other loci (CTLA4 and IL2-21/4q27) so that a total
of 13 loci have now been conﬁrmed as associated with RA sus-
ceptibility (HLA DRB1, PTPN22, STAT4, TRAF1/C5, 6q23,
IL2RB, 12q13, 10p15, CD40, MMEL1, AFF3, 4q27 and
CTLA-4). Interestingly, for all but one of these loci (TRAF1/
C5), association with other autoimmune diseases, including
systemic lupus erythematosus, Graves disease and coeliac
disease, has been described, ﬁrmly establishing the concept of
common susceptibility loci for autoimmunity.
MATERIALS AND METHODS
Sample collections
Patients with RA (n ¼ 3,962) were recruited from six centres
(Manchester, Shefﬁeld, Leeds, Aberdeen, Oxford and London)
across the UK as described previously (2). All cases were Cau-
casian of Northern European descent and all fulﬁlled the 1987
American College of Rheumatology classiﬁcation criteria
modiﬁed for genetic studies (20,21). Clinical and demographic
characteristics of the cohort are detailed in Supplementary
Material, Table S2. Brieﬂy, 72% subjects were female, 72%
were rheumatoid factor positive and 68% carried ACPA
antibodies as recognized by the anti-CCP antibody test.
Therefore, this cohort is representative of a hospital-based
series of RA subjects. Healthy Caucasian controls (n ¼
3531) were recruited from ﬁve of the six centres (cases only
recruited from London). All participants were recruited after
providing informed consent and the study was approved by
the North West Research Ethics Committee (MREC 99/8/
84). Additional patient samples (n ¼ 997) from subjects satis-
fying ACR criteria for RA (20,21) were obtained from an
inception cohort of patients with inﬂammatory polyarthritis
recruited from the Norfolk Arthritis Register (NOAR).
Sixty-eight percent of patients were female, 39% were RF
positive at baseline and 52% had developed erosions by 5
years. Local Ethics approval was obtained and all patients pro-
vided informed consent (LREC 2003-075).
Immunogenetics
Serum RF and anti-CCP antibody titre were measured using
commercially available kits [RF-PAIA Immunoturbidimetric
Assay for rheumatoid factor, DiastatTM Anti-CCP Kit
(Axis-Shield Diagnostics Limited, UK)]. Patients with titres
 40 units/ml and  5 units/ml were deﬁned as positive for
RF and anti-CCP antibodies, respectively. Anti-CCP status
was available only for a subset of the total validation case
cohort (n ¼ 2370).
Genotyping
Genotyping was performed using the Sequenom iPlex plat-
form (www.sequenom.com) according to the manufacturer’s
instructions. All genotyping was performed at the arc Epide-
miology Unit, Manchester. Details of the primer and probe
sequences used for the SNPs are available on request. Only
samples and SNPs exceeding a 90% success rate were used
in the analysis.
Analysis
Genotype counts in cases and controls were analysed using
PLINK software using the x
2 test for trend (22). A corrected
signiﬁcance threshold of P , 0.004 was selected based on a
Bonferroni correction for 14 independent loci tested as part
of this study. Power calculations were performed using the
CaTS power calculator tool (http://www.sph.umich.edu/csg/
abecasis/cats/). Stratiﬁcation analysis was performed by sub-
grouping the cases into anti-CCP antibody positive and nega-
tive subgroups for comparison with the controls. Stepwise
logistic regression was used to determine whether the associ-
ation observed at the AFF3 locus was primarily due to
linkage disequilibrium between the associated SNPs or
whether independent effects existed. The possibility of popu-
lation stratiﬁcation was not examined because genome-wide
data was only available for the WTCCC data set. However,
in that cohort, no evidence for global population stratiﬁcation
in the UK population tested was identiﬁed (lGC ¼ 1.03 for RA
samples versus controls) and allele frequencies in the two
other UK control cohorts examined as part of the current
study did not differ from the control cohort tested as part of
the WTCCC study (1).
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